VNDA Vanda Pharmaceuticals Inc.

16.65
+0.01  (+0%)
Previous Close 16.64
Open 16.65
Price To Book 3.18
Market Cap 876501854
Shares 52,642,754
Volume 434,949
Short Ratio
Av. Daily Volume 928,148

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2Q 2019.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
PDUFA date August 16, 2019.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 data released December 10, 2018 - one of two primary endpoints met. sNDA filing due 3Q 2019.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 data due 1H 2020.
Tradipitant
Atopic dermatitis
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies
Phase 2 data due 2Q 2019.
Tradipitant
Motion sickness

Latest News

  1. Vanda Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
  2. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CORT, CAG and VNDA
  3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
  4. SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. – VNDA
  5. INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  6. SHAREHOLDER ALERT: DPLO VNDA BA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  7. Class Action - Bronstein, Gewirtz & Grossman, LLC Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)
  8. SHAREHOLDER ALERT: VNDA SYNH WSR FSNN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  9. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, Syneos, Weight Watchers, and Mattel and Encourages Investors to Contact the Firm
  10. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VNDA, INGN and NIO
  11. IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  12. A Securities Class Action Has Been Filed Against Vanda; Block & Leviton LLP Encourages Shareholders to Contact the Firm
  13. CLASS ACTION UPDATE for T, VNDA, EB and CRCM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  14. FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  15. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of STMP, VNDA and MWA
  16. Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)
  17. FILING DEADLINE -- Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of T, CAG and VNDA
  18. Bronstein, Gewirtz & Grossman, LLC Class Action Update Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)
  19. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of T, VNDA, USX and BV